Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting
/
February 3, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from non-human primate studies of the company s proprietary fully human Interleukin 12 (IL-12) therapeutic candidate, SON-1010, will be presented at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting 2021, April 10-15 and May 17-21.
Details of the abstract and poster presentation are as follows:
Title: Toxicity profile of interleukin 12 attached to a fully human albumin binding domain (FHABTM) in Cynomolgus macaques
Abstract Number: 1589
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Sonnet BioTherapeutics Completes Successful Repeat Dose Study of SON-1010 in Non-Human Primates
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Arcellx Appoints Rami Elghandour as Chairman and Chief Executive Officer
January 26, 2021 16:00 ET | Source: Arcellx, Inc. Arcellx, Inc. Gaithersburg, Maryland, UNITED STATES
GAITHERSBURG, Md., Jan. 26, 2021 (GLOBE NEWSWIRE) Arcellx, a privately held clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced the appointment of Rami Elghandour as Chairman of the Board and Chief Executive Officer, effective Jan. 22, 2021. Arcellx’s founder and CEO, David Hilbert, Ph.D., will transition to the new role of Chief Technical Officer.
“I’m thrilled to join Arcellx and honored to lead the company as it advances its transformative cancer and autoimmune therapies,” said Rami Elghandour. “The results from Arcellx’s Phase I study in multiple myeloma validate the company’s proprietary technology and demonstrate the potential for a best-in-class therapy for many patients in ne